Mylan Inc. (MYL) Given "Buy" Rating by Citigroup (C) Analysts
Monday, June 27, 2021 12:10 PM

Equities research analysts at Citigroup (NYSE: C) reiterated a "buy" rating on shares of Mylan Inc. (NYSE: MYL) in a research note to investors on Monday.

Separately, analysts at JPMorgan Chase & Co. (NYSE: JPM) reiterated an "overweight" rating on shares of Mylan Inc. in a research note to investors on Friday. Also, analysts at Argus upgraded shares of Mylan Inc. from a "hold" rating to a "buy" rating in a research note to investors on Tuesday, May 24th. They now have a $29.00 price target on the stock.

Shares of Mylan Inc. traded up 0.13% during mid-day trading on Tuesday, hitting $23.14. Mylan Inc. has a 52 week low of $16.55 and a 52 week high of $25.46. The stock's 50-day moving average is $23.98 and its 200-day moving average is $22.39. The company has a market cap of $10.164 billion and a price-to-earnings ratio of 31.74.

Mylan Inc. last announced its quarterly results on Tuesday, May 3rd. The company reported $0.44 earnings per share (EPS) for the previous quarter, meeting the Thomson Reuters consensus estimate of $0.44 EPS. During the same quarter in the prior year, the company posted $0.36 earnings per share. The company’s quarterly revenue was up 12.40% on a year-over-year basis. On average, analysts predict that Mylan Inc. will post $0.54 EPS next quarter.

Mylan Inc. (Mylan) is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic pharmaceuticals, specialty pharmaceuticals and active pharmaceutical ingredients (APIs). It operates through two business segments: Generics and Specialty. The Generics Segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule or transdermal patch form, as well as API. The Specialty Segment engages mainly in the manufacture and sale of branded specialty nebulized and injectable products. As of December 31, 2009, Mylan marketed more than 900 different products covering an array of therapeutic categories to consumers in more than 140 countries and territories across the globe. During the year ended December 31, 2009, the Company acquired approximately 25% of the remaining interest in Matrix Laboratories Limited, bringing both its total ownership and control to over 96%.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.